Skip to main content

Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy.

Author
Abstract
:

Although pharmacogenomics has evolved substantially, a predictive test for chemotherapy toxicity is still lacking. We compared the toxicity of adjuvant dose-dense doxorubicin-cyclophosphamide (ddAC) and docetaxel-doxorubicin-cyclophosphamide (TAC) in a randomized multicenter phase III trial and replicated previously reported associations between genotypes and toxicity.

Year of Publication
:
2017
Journal
:
Oncotarget
Volume
:
8
Issue
:
69
Number of Pages
:
113531-113542
Date Published
:
2017
DOI
:
10.18632/oncotarget.22697
Short Title
:
Oncotarget
Download citation